SMN2 and proximal spinal muscular atrophy: It was developed by AveXis, a Novartis company, for the treatment of paediatric patients aged <2 years with SMA and bi-allelic mutations in the primary gene encoding the survival motor neuron protein, namely the SMN1 gene.